MedTrace Logo

Diphenhydramine and Sweating

NCT05586477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-09-13

No results posted yet for this study

Summary

In 2012, it was estimated that nearly 1 in 4 Canadians suffer from allergic rhinitis. To add, 78% of individuals working in predisposing environments are predicted to develop occupational rhinitis. Currently, the most popular treatment for rhinitis is antihistamine medication such as diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®. Due it its anticholinergic effects, diphenhydramine has been suggested to impair the whole body sweating response during heat stress, potentially leaving consumers at an increased risk of heat-related illness. This randomized control trial approved by Health Canada will investigate whether ingesting extra strength diphenhydramine (50mg) will alter whole-body sweat losses during 60 minutes of exercise.

Conditions

  • Diphenhydramine Causing Adverse Effects in Therapeutic Use
  • Hyperthermia
  • Allergic Rhinitis
  • Sweating

Interventions

DRUG

Placebo

A placebo pill (i.e., sugar) will be consumed 2 h before intervention.

DRUG

Diphenhydramine

Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention

Sponsors & Collaborators

  • Lakehead University

    lead OTHER

Principal Investigators

  • Nicholas Ravanelli, PhD · Lakehead University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-21
Primary Completion
2023-06-23
Completion
2023-06-23

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05586477 on ClinicalTrials.gov